Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Join The 'Real World' Under PDUFA VI

Executive Summary

Regulators pledge to explore the use of real-world evidence, strengthen the patient's voice in drug review, and boost the agency's postmarketing surveillance abilities as part of sixth round of user fee program with industry.

Advertisement

Related Content

FDA Patient Feedback Meetings: External Model Ramping Up In 2017
Duke's McClellan: Changing Drug Development Policy From Outside FDA
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
PDUFA's 'Real-World' Journey Expected To Be Slow Walk
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
PDUFA VI launches: Not Pluto flyby, but has potential
Educating Califf: Eyes opened on PDUFA, patient advocates

Topics

Advertisement
UsernamePublicRestriction

Register

PS118788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel